Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

Oral semaglutide reduced major cardiovascular ... according to late-breaking results from the phase 3 SOUL trial. 1 These findings were presented Saturday, March 29, at the American College ...

Both the injectable and oral forms of semaglutide ... such as heart attacks and stroke. The Semaglutide cardiOvascular oUtcomes triaL (SOUL) recruited 9,650 people for the study who had pre ...

Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial1.Data ...

Novo Nordisk’s SOUL trial confirms that oral semaglutide significantly reduces the risk of heart attack, stroke, and ...

Preventive cardiologist Neha Pagidipati, MD (Duke University School of Medicine, Durham, NC), called SOUL an important clinical trial because it confirms the cardiovascular benefits of oral ...

Once-daily orforglipron was more effective than placebo and just as safe as injectable GLP-1s in patients with diabetes and ...

Both the injectable and oral forms of semaglutide ... such as heart attacks and stroke. The Semaglutide cardiOvascular oUtcomes triaL (SOUL) recruited 9,650 people for the study who have pre ...

Separately, in the SOUL trial of people with T2D who also had atherosclerotic cardiovascular disease and/or chronic kidney disease (CKD), several years of oral semaglutide (Rybelsus) reduced one's ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus ® (oral semaglutide) significantly reduced the risk of major adverse ...